b'The MyMRD is a NGS-based panel that assesses variants in hotspots from 23 genes that commonly drive myeloid malignancies, including AML, MPN and MDS. It can detect SNVs, indels, and translocations to the genomic basepair, offering unparalleled precision and detection of low level mutations in patients. The MyMRD assay detects at least one driver mutation in 90%-95% of all AMLs.Consider testing with MyMRD as an entry point into clinical trials or to optimize treatment and monitor tumor-specific markersPatient with suspected orB- and T-cell confirmed hematologicalclonality testing malignancy accordingto disorderFollow-up with MRD assays unique for biomarkers identified in each patient, such as FLT3 ITD MRD and NPM1 MRD MyMRD is a CLIA validated assay.LabPMM Services Catalog 2021|55'